Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC boosted its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 26.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 117,958 shares of the biopharmaceutical company’s stock after buying an additional 24,557 shares during the period. Stoneridge Investment Partners LLC owned approximately 0.06% of Esperion Therapeutics worth $262,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ESPR. BOKF NA acquired a new position in shares of Esperion Therapeutics during the second quarter worth $26,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics in the first quarter valued at approximately $37,000. Simplicity Wealth LLC acquired a new position in Esperion Therapeutics during the 1st quarter valued at approximately $44,000. State Board of Administration of Florida Retirement System bought a new position in shares of Esperion Therapeutics during the first quarter worth about $50,000. Finally, National Bank of Canada FI increased its holdings in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Monday, August 12th. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $1.91 on Friday. Esperion Therapeutics, Inc. has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a 50 day moving average price of $2.06 and a 200 day moving average price of $2.25. The stock has a market capitalization of $374.80 million, a price-to-earnings ratio of -1.93 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million. On average, sell-side analysts expect that Esperion Therapeutics, Inc. will post -0.04 EPS for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.